Videos

Frederic Amant, MD, PhD, assistant professor, gynecologic oncologist, head of the scientific section of gynecologic oncology at Katholieke Universiteit in Leuven, Belgium, the impacts of chemotherapy on pregnant woman and their babies.

Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH University of Aachen, discusses an observational cohort study looking at breast MRI screening of women at average risk of breast cancer.

Neal D. Shore, MD, FACS, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.

Howard M. Sandler, MD, MS, FASTRO, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma.

David J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).